Top Story Today
40 Years of Failure, Then a Drug That Nearly Doubled Survival in Pancreatic Cancer
Revolution Medicines' daraxonrasib just did what four decades of drug development couldn't: it cracked the RAS oncogene, the single most common cancer-driving mutation in humans. In a 500-patient Phase 3 trial, previously treated pancreatic cancer patients on daraxonrasib lived a median of 13.2 months versus 6.7 months on chemo, cutting the risk of death by 60%. Over half of treated patients were alive at one year, compared to fewer than one in five on chemotherapy. RAS mutations fuel roughly 20% of all human cancers, and until recently, zero approved drugs could target them directly.
Why it matters: RAS mutations drive an estimated 3 to 4 million new cancer cases globally each year, spanning pancreatic, colorectal, lung, and other tumors. A multi-selective inhibitor proving this level of efficacy could rewrite treatment playbooks across oncology's largest and most stubborn molecular subgroup.
Read more →Clinical Trials and Drug Development
A Two-in-One Cancer Drug Just Beat Immunotherapy's Gold Standard in Lung Cancer
Nothing has ever beaten a PD-1 inhibitor plus chemo on overall survival in first-line squamous lung cancer. Akeso's ivonescimab, a bispecific antibody targeting both PD-1 and VEGF, just did exactly that: 27.9 months median survival versus 23.7 months, a 34% reduction in death risk. At two years, 16 more patients out of every 100 were alive on the new drug. The real test comes when it faces Keytruda in a global trial.
Read more →Gilead's $21 Billion Bet on Trodelvy Can't Crack Lung Cancer
Trodelvy's second lung cancer trial, EVOKE-03, was stopped early for futility after the drug failed to improve survival when added to Keytruda in first-line NSCLC. That's now 0-for-2 in lung cancer for a drug Gilead acquired for $21 billion. Rivals Merck/Kelun-Biotech just showed a competing TROP-2 ADC cutting progression risk by 65% in the same setting.
Read more →One in Four Hep B Patients Achieved a Functional Cure After Six Months of Treatment
For the first time, a Phase 3 trial shows a finite therapy can functionally cure chronic hepatitis B. GSK's bepirovirsen delivered a 26% cure rate in selected patients versus 0% on placebo, with patients staying virus-free nearly a year after stopping all treatment. The current standard of care achieves about 3 to 5% over years of daily pills. An FDA decision is expected by October 2026.
Read more →One FDA Meeting Erased an Entire Biotech Company Overnight
Fulcrum Therapeutics' sickle cell drug pociredir was hitting its targets and showing no safety problems of its own. Then the FDA declared that the entire PRC2 drug class carries cancer risk, regardless of individual data, after a related drug was pulled from the market. Fulcrum scrapped its only program, cut 85% of staff, and became a $333 million cash shell in search of a buyer.
Read more →Deals and Geopolitics
The Pentagon Just Labeled Biotech's Biggest Supplier a Chinese Military Company
WuXi AppTec, which serves 6,000 customers across 30 countries and helped manufacture Lilly's blockbuster Zepbound, just landed on the Pentagon's Chinese military company blacklist. The designation triggers Biosecure Act restrictions that could force hundreds of pharma companies to find new manufacturing partners. Shares plunged roughly 6%, and analysts estimate roughly $30 billion in cumulative U.S.-linked revenue is at risk through 2030.
Read more →Novartis Writes a Billion-Dollar Check for Molecular Glue Drugs
Novartis signed a molecular glue deal with Orionis Biosciences worth $40 million upfront and up to $1.4 billion in milestones. The technology tricks disease-causing proteins into self-destructing, targeting the roughly 80% of proteins that traditional drugs can't touch. Big Pharma's spending spree on this approach now includes parallel bets from Roche and Gilead.
Read more →Lilly Pays Up to $3 Billion for Five Mystery Programs From a Chinese Biotech
Eli Lilly agreed to pay $87 million upfront (up to $3 billion total) to Haisco Pharmaceutical for five undisclosed early-stage programs. It's part of Lilly's accelerating China shopping spree; the company has committed over $13 billion in potential deal value to Chinese partners in 2026, funded by its GLP-1 cash machine.
Read more →Science and Regulatory Milestones
Over Two Dozen ASCO Studies Link Ozempic and Mounjaro to Lower Cancer Risk
A flood of observational data at ASCO 2026 found GLP-1 users had 38 to 50% lower odds of cancer spreading in lung, breast, colorectal, and liver tumors. One study linked the drugs to a 34% mortality reduction across six solid tumor types. The signal is consistent across independent teams, though experts stress it's observational, not proof. Randomized trials are likely years away.
Read more →Japan Approves the World's First Cancer-Killing Adenovirus
Japan granted full marketing approval to Telomelysin, a genetically engineered virus that selectively infects and destroys cancer cells by exploiting their reliance on the enzyme telomerase. In a U.S. Phase 1 trial, all 13 evaluable esophageal cancer patients achieved complete responses at the treated site. The approval validates the oncolytic virus modality in a major regulatory market.
Read more →America's Sunscreen Finally Caught Up to the Rest of the World
The FDA issued a proposed order for bemotrizinol, the first new sunscreen active ingredient to advance through the regulatory process in over 20 years. Europeans have been using it since 2000. The filter covers both UVA and UVB, stays stable under intense sun, and skips the white cast that makes mineral sunscreens unpopular. Products could hit shelves by late summer 2026, with more modern UV filters potentially following through the same streamlined pathway.
Read more →